Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.65 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756947 | 1.00 | DAO (0.65) | DAOATAD2BRD4AURKAPARP1 | |
| SCHEMBL22185856 | 0.79 | DAO (0.61) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL15528142 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL21226786 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL1574005 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL3714541 | 0.79 | DAO (1.00) | DAOAURKAPARP1RIPK1 | |
| SCHEMBL668758 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL671495 | 0.79 | DAO (0.65) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL4316781 | 0.78 | DAO (0.59) | DAOAURKAPARP1RIPK1CCNB2 | |
| SCHEMBL17131587 | 0.78 | DAO (0.59) | DAOAURKAPARP1RIPK1CCNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-9695176-B2 | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-04 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20150011569-A1 | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF | DREXEL UNIVERSITY | 2015-01-08 | — | — | US | disclosed |
| US-20150011569-A1 | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF | DREXEL UNIVERSITY | 2015-01-08 | — | — | US | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2009032124-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1978966-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | Amira Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008047883-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | WO | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005123685-A1 | TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | DAO 207/4885ATAD2 2848/4885BRD4 2095/4885 |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | DAO 4439/4885ATAD2 4005/4885BRD4 1726/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | DAO 4497/4885ATAD2 3698/4885BRD4 1525/4885 |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | DAO 727/4885ATAD2 3278/4885BRD4 66/4885 |
| US-20220152014-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | DAO 4439/4885ATAD2 4005/4885BRD4 1726/4885 |
| US-20150011569-A1 | NOVEL P13K p110 INHIBITORS AND METHODS OF USE THEREOF | PIK3R5, PIK3R4, PIK3CD | DAO 4314/4885ATAD2 2023/4885BRD4 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.